Diamond Institute for Infertility and Menopause – FDA 483, Feb 23, 2022
The FDA inspected Diamond Institute for Infertility and Menopause in Millburn, NJ, and found significant deficiencies related to donor eligibility determination and screening for communicable diseases. The firm failed to properly screen donors with reactive test results or incomplete medical histories, shipped HCT/Ps without complete eligibility, and lacked adequate screening procedures, including for Zika Virus. These issues indicate a serious risk of transmitting communicable diseases through reproductive tissues.
- Inspection date
- February 23, 2022
- Product type
- biologics
ID · 45726846-9102-470f-814c-a4cdb461274f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.